Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026388 · ClinicalTrials.gov registry record
Rare Kidney Stone Consortium Biobank
A clinical trial of Dent Disease and Cystinuria, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT02026388 is a study of Dent Disease and Cystinuria that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 2,000 participants, above the 278-participant average among 4 other Dent Disease trials with a reported enrollment target (619% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02026388, a study of Dent Disease and Cystinuria, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2013-05 |
| Est. Completion | 2030-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026388
The ClinicalTrials.gov registry entry for NCT02026388 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 278-participant average among 4 other Dent Disease trials with a reported enrollment target (619% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Dent Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02026388 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02026388 about?
NCT02026388 is a clinical study titled "Rare Kidney Stone Consortium Biobank". This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.
What is the current status of trial NCT02026388?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2013-05. Estimated completion is 2030-06.
What conditions does trial NCT02026388 study?
This clinical trial studies the following conditions: Dent Disease, Cystinuria, Primary Hyperoxaluria, APRT Deficiency.
Who is sponsoring clinical trial NCT02026388?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02026388 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dent Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.